Kenneth Greenberg, PhD

Dr. Kenneth Greenberg is Co-Founder, President, and CEO of SonoThera. He has spent more than 20 years building companies and advancing innovative therapies across diverse disease areas and modalities, including viral and non-viral gene therapy, gene editing, oligonucleotides, recombinant proteins, immunotherapy, and small molecules. Prior to founding SonoThera, Dr. Greenberg led External Innovation efforts in Cell & Gene Therapy at Janssen (Johnson & Johnson) for Western North America, Australia, and New Zealand, supporting strategic partnerships in Cell & Gene Therapy, Antibody & Protein Therapeutics, Gene Editing, and CMC across all therapeutic areas. Prior to Janssen, he created and led the neuroscience discovery program at UNITY Biotechnology, advancing senolytic and protein-based therapeutic programs for neurodegenerative and neuropsychiatric disorders. Earlier in his career, Dr. Greenberg co-founded CODA Biotherapeutics, where he led financing and strategic company-building efforts, directed preclinical discovery, and co-invented an AAV-based chemogenetic neuromodulation platform for neuropathic pain, epilepsy, and other neurological disorders. He also co-founded Oncorus, where he helped lead financing, directed scientific strategy, and co-invented a microRNA-attenuated HSV-based oncolytic immunotherapy platform. Dr. Greenberg earned his Ph.D. in Visual Neuroscience and completed a Kirschstein-NRSA postdoctoral fellowship in MCB Neurobiology at the University of California, Berkeley. He is an inventor on over two dozen patents and patent applications, co-authoring more than 50 scientific publications.